Tezacaftor - Latest Advances

Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis.

Journal: Therapeutic advances in respiratory disease

Published: October 09, 2025

(R)-vanzacaftor potentiates BKCa channels in the absence of CFTR correction or potentiation.

Journal: American journal of physiology. Cell physiology

Published: September 08, 2025

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Journal: American journal of respiratory and critical care medicine

Published: August 11, 2025

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Journal: The Journal of clinical investigation

Published: August 07, 2025

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Journal: The Journal of clinical investigation

Published: August 07, 2025

Divergent Neurobehavioral Effects of CFTR Modulators Elexacaftor and Ivacaftor in Mice.

Journal: bioRxiv : the preprint server for biology

Published: July 09, 2025

Assessing CFTR Function and Epithelial Morphology in Human Nasal Respiratory Cell Cultures: A Combined Immunofluorescence and Electrophysiological Study.

Journal: International journal of molecular sciences

Published: July 02, 2025

Effects of GM1 ganglioside and its derivatives on ETI-rescued F508del-CFTR maturation and host-pathogen interactions in cystic fibrosis bronchial cells.

Journal: Glycoconjugate journal

Published: June 23, 2025

CFTR Modulators Counteract F508del CFTR Functional Defects in a Pancreatic Epithelial Model of Cystic Fibrosis.

Journal: Life (Basel, Switzerland)

Published: June 13, 2025

A 3-Week Inpatient Rehabilitation Programme Improves Body Composition in People with Cystic Fibrosis with and Without Elexacaftor/Tezacaftor/Ivacaftor Therapy.

Journal: Nutrients

Published: June 13, 2025

CFTR mutation leads to intrinsic dysfunction in neutrophils from people with Cystic Fibrosis.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2025

Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: June 10, 2025

Filters

Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis.

Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis.

(R)-vanzacaftor potentiates BKCa channels in the absence of CFTR correction or potentiation.

(R)-vanzacaftor potentiates BKCa channels in the absence of CFTR correction or potentiation.

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Divergent Neurobehavioral Effects of CFTR Modulators Elexacaftor and Ivacaftor in Mice.

Divergent Neurobehavioral Effects of CFTR Modulators Elexacaftor and Ivacaftor in Mice.

Assessing CFTR Function and Epithelial Morphology in Human Nasal Respiratory Cell Cultures: A Combined Immunofluorescence and Electrophysiological Study.

Assessing CFTR Function and Epithelial Morphology in Human Nasal Respiratory Cell Cultures: A Combined Immunofluorescence and Electrophysiological Study.

Effects of GM1 ganglioside and its derivatives on ETI-rescued F508del-CFTR maturation and host-pathogen interactions in cystic fibrosis bronchial cells.

Effects of GM1 ganglioside and its derivatives on ETI-rescued F508del-CFTR maturation and host-pathogen interactions in cystic fibrosis bronchial cells.

CFTR Modulators Counteract F508del CFTR Functional Defects in a Pancreatic Epithelial Model of Cystic Fibrosis.

CFTR Modulators Counteract F508del CFTR Functional Defects in a Pancreatic Epithelial Model of Cystic Fibrosis.

A 3-Week Inpatient Rehabilitation Programme Improves Body Composition in People with Cystic Fibrosis with and Without Elexacaftor/Tezacaftor/Ivacaftor Therapy.

A 3-Week Inpatient Rehabilitation Programme Improves Body Composition in People with Cystic Fibrosis with and Without Elexacaftor/Tezacaftor/Ivacaftor Therapy.

CFTR mutation leads to intrinsic dysfunction in neutrophils from people with Cystic Fibrosis.

CFTR mutation leads to intrinsic dysfunction in neutrophils from people with Cystic Fibrosis.

Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry.

Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry.